Cardiological Findings in Children and Adolescents Before and After Guanfacine Treatment for Attention Deficit and Hyperactivity Disorder

被引:0
|
作者
Yukcu, Bekir [1 ]
Onal, Bedia Sultan [2 ]
Osmanli, Cansu Cobanoglu [2 ]
Tonkaz, Gulsum Yitik [2 ]
Sahin, Berkan [2 ]
机构
[1] Giresun Matern & Children Training & Res Hosp, Dept Pediat Cardiol, TR-28200 Giresun, Turkiye
[2] Giresun Univ, Dept Child & Adolescent Psychiat, Fac Med, TR-28200 Giresun, Turkiye
来源
CHILDREN-BASEL | 2025年 / 12卷 / 03期
关键词
ADHD; guanfacine; cardiovascular safety; electrocardiography; EXTENDED-RELEASE GUANFACINE; DEFICIT/HYPERACTIVITY DISORDER; DOUBLE-BLIND; ALPHA-2; AGONISTS; LONG-TERM; TP-E/QT; ADHD; STIMULANT; PSYCHOSTIMULANTS; METAANALYSIS;
D O I
10.3390/children12030302
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective: This study evaluates the short-term cardiovascular effects of guanfacine treatment in children and adolescents with attention deficit/hyperactivity disorder (ADHD). The treatment's impact on novel electrocardiographic parameters was also investigated. Methods: In a retrospective study conducted between January 2023 and June 2024, 37 patients aged 6-18 years with ADHD underwent baseline and follow-up cardiac evaluations including electrocardiography (ECG) and blood pressure measurements. Novel ECG markers (QRS-T angle, QT dispersion, QTc dispersion, Tp-e interval, Tp-e dispersion, Tp-e/QT ratio, and Tp-e/QTc ratio) were analyzed alongside standard parameters such as heart rate, QT, and corrected QT (QTc) intervals. Guanfacine was initiated at 1 mg and titrated weekly until an optimal clinical response was achieved. Results: Guanfacine treatment led to a significant reduction in heart rate (-12.3 bpm; p < 0.001) and P wave axis (-12.3 degrees; p = 0.038) and an increase in QT interval (+16.8 ms; p = 0.014). However, no significant changes were observed in blood pressure, QTc duration, or the novel ECG parameters. Importantly, the absence of any changes in these advanced markers supports the cardiovascular safety of guanfacine. Two patients experienced side effects (bradycardia and hypotension), leading to treatment discontinuation. ANCOVA analysis indicated that the duration between ECG evaluations significantly influenced the QT interval changes, emphasizing the importance of timing when monitoring cardiovascular effects. Conclusions: Guanfacine demonstrated minor, statistically significant effects on the selected cardiac parameters without clinically meaningful changes to or adverse impacts on the novel ECG markers investigated. As extended-release guanfacine has only been available in T & uuml;rkiye for the management of ADHD for approximately two years, studies evaluating its clinical efficacy and side effects are critical for clinicians working in this field.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Guanfacine for the treatment of attention deficit hyperactivity disorder in children and adolescents
    Rizzo, Renata
    Martino, Davide
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2015, 15 (04) : 347 - 354
  • [2] GUANFACINE EXTENDED RELEASE IN THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN AND ADOLESCENTS
    Connor, D. F.
    Rubin, J.
    DRUGS OF TODAY, 2010, 46 (05) : 299 - 314
  • [3] Guanfacine extended release for the treatment of attention-deficit/hyperactivity disorder in children and adolescents
    Connor, Daniel F.
    Arnsten, Amy F. T.
    Pearson, Geraldine S.
    Greco, Gabriella F.
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (11) : 1601 - 1610
  • [4] Guanfacine Extended Release: A Novel Treatment for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents
    Faraone, Stephen V.
    McBurnett, Keith
    Sallee, Floyd R.
    Steeber, Jennifer
    Lopez, Frank A.
    CLINICAL THERAPEUTICS, 2013, 35 (11) : 1778 - 1793
  • [5] BMI Changes in Children and Adolescents with Attention Deficit Hyperactivity Disorder Before and After Treatment with Methylphenidate
    Kousha, Maryam
    Dalili, Setila
    Kiani, Seyyed Amir
    Zare, Maryam
    Karambin, Mohammad Mahdi
    Heidarzadeh, Abtin
    Koohmanaee, Shahin
    Rad, Afagh Hassanzadeh
    IRANIAN JOURNAL OF PEDIATRICS, 2018, 28 (02)
  • [6] Guanfacine use in children with attention deficit hyperactivity disorder
    Cohn, LM
    Caliendo, GC
    ANNALS OF PHARMACOTHERAPY, 1997, 31 (7-8) : 918 - 919
  • [7] Guanfacine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents with Down Syndrome: A Retrospective Chart Review
    Powers, James H.
    Wu, Michael
    Palumbo, Michelle
    Keary, Christopher J.
    Mcdougle, Christopher J.
    Ravichandran, Caitlin
    Thom, Robyn P.
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2024, 34 (02) : 95 - 103
  • [8] GUANFACINE FOR TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER IN BOYS
    HORRIGAN, JP
    BARNHILL, LJ
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 1995, 5 (03) : 215 - 223
  • [9] Response to Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD)
    Turnbow, John
    Kollins, Scott
    Lopez, Frank
    Lyne, Andrew
    Youcha, Sharon
    Rubin, Jonathan
    BIOLOGICAL PSYCHIATRY, 2010, 67 (09) : 218S - 218S
  • [10] Attention deficit hyperactivity disorder in children and adolescents
    Flisher, A. J.
    Hawkridge, S.
    SOUTH AFRICAN JOURNAL OF PSYCHIATRY, 2013, 19 (03) : 136 - 140